Current Report Filing (8-k)
17 December 2015 - 8:12AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): December 12, 2015
AMPIO PHARMACEUTICALS, INC.
(Exact name of registrant as specified in Charter)
|
|
|
|
|
Delaware |
|
001-35182 |
|
26-0179592 |
(State or other jurisdiction of
incorporation or organization) |
|
(Commission
File No.) |
|
(IRS Employer
Identification No.) |
373 Inverness Parkway, Suite 200
Englewood, Colorado 80112
(Address of principal executive offices, including zip code)
(720) 437-6500
(Registrants telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.07 |
Submission of Matters to a Vote of Security Holders. |
Ampio Pharmaceuticals, Inc. (the
Company) held its Annual Meeting of Stockholders on December 12, 2015. The number of shares of common stock entitled to vote at the annual meeting was 51,998,306. The number of shares of common stock present, in person or
represented by proxy, and entitled to vote at the annual meeting was 41,114,423. All matters submitted to a vote of our stockholders at the annual meeting were approved and all director nominees were elected.
The certified results of each of the matters voted upon at the annual meeting, which are more fully described in our definitive proxy
statement, are as follows:
(1) Election of five (5) directors for terms expiring at the 2016 annual meeting of stockholders.
|
|
|
|
|
DIRECTORS |
|
FOR |
|
WITHHELD |
Michael Macaluso |
|
14,094,337 |
|
889,046 |
David Bar-Or, M.D. |
|
14,469,337 |
|
514,046 |
Philip H. Coelho |
|
12,966,360 |
|
2,017,023 |
Richard B. Giles |
|
13,171,175 |
|
1,812,208 |
David R. Stevens, Ph.D. |
|
12,800,875 |
|
2,182,508 |
There were 26,131,040 broker non-votes regarding this proposal.
(2) Approval, on an advisory basis, of the compensation of the Companys named executive officers as disclosed in the definitive proxy
statement.
|
|
|
|
|
FOR |
|
AGAINST |
|
ABSTAIN |
12,319,696 |
|
949,285 |
|
1,714,402 |
There were 26,131,040 broker non-votes regarding this proposal.
(3) Ratification of the selection of EKS&H LLLP as the Companys independent registered public accounting firm for the fiscal year
ending December 31, 2015.
|
|
|
|
|
FOR |
|
AGAINST |
|
ABSTAIN |
40,011,746 |
|
976,230 |
|
126,447 |
There were no broker non-votes regarding this proposal.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
AMPIO PHARMACEUTICALS, INC. |
|
|
By: |
|
/s/ Gregory A. Gould |
|
|
Gregory A. Gould Chief Financial
Officer |
Dated: December 16, 2015
Ampio Pharmaceuticals (AMEX:AMPE)
Historical Stock Chart
From Jun 2024 to Jul 2024
Ampio Pharmaceuticals (AMEX:AMPE)
Historical Stock Chart
From Jul 2023 to Jul 2024